A United Kingdom supplier, with 2 awarded contracts, totalling £2, most recently 11 months ago.
This contract involves establishing active ingredient-based discount agreements in accordance with § 130a Abs. 8 SGB V for specific pharmaceuticals. The agreements will be in effect for a maximum period of 24 months, starting no earlier than April 1, 2026, and ending uniformly on March 31, 2028. Sup
The DAK-Gesundheit is seeking to establish a non-exclusive discount agreement for the drug Olopatadine (ATC S01GX09) under Section 130a, Paragraph 8 of the German Social Code (SGB V). This agreement will be effective from September 1, 2024, to August 31, 2026. The process will involve formal procure
